EFS and OS in patients with or without high BCL2/MYC coexpression. Overall EFS and OS in patients with or without high BCL2/MYC coexpression determined by RNA-seq in the placebo plus R-CHOP (A,B) and ibrutinib plus R-CHOP (C,D) arms.